骨粗鬆症治療薬市場レポート：2030年までの動向、予測、競合分析

骨粗鬆症治療薬の動向と予測

世界の骨粗鬆症治療薬市場は、2024年から2030年までのCAGRが3.2%で、2030年までに推定172億米ドルに達すると予想されます。この市場の主な促進要因は、世界中で骨粗鬆症の発生が増加していることと、高齢者人口が増加していることです。世界の骨粗鬆症治療薬市場の将来は、原発性骨粗鬆症市場と続発性骨粗鬆症市場にビジネスチャンスがあり、有望視されています。

骨粗鬆症治療薬市場洞察

Lucintelは、骨折リスクの高い患者の骨粗鬆症治療にRANKL阻害剤の採用が増加していることから、予測期間中、RANKL阻害剤が最大セグメントであり続けると予測しています。

同市場では、高齢化人口の急増と消費者の骨粗鬆症に対する意識の高まりから、原発性骨粗鬆症が引き続き大きなセグメントを占めると思われます。

北米は、大手企業の存在、骨粗鬆症患者の増加、同地域におけるブランド医薬品の入手のしやすさなどから、予測期間を通じて最大の地域であり続けると思われます。

本レポートでは、以下の11の主要な質問に回答しています：

• Q.1.市場セグメントのうち、最も有望かつ高成長な機会は何か？
• Q.2.どのセグメントがより速いペースで成長するのか、またその理由は？
• Q.3.今後成長が加速すると思われる地域とその理由は？
• Q.4.市場力学に影響を与える主な要因は何か？市場における主な課題とビジネスリスクは？
• Q.5.この市場におけるビジネスリスクと競合の脅威は？
• Q.6.この市場における新たな動向とその理由は？
• Q.7.市場における顧客の需要の変化にはどのようなものがありますか？
• Q.8.この市場における新たな開発と、その開発をリードしている企業は？
• Q.9.この市場における主要企業は？主要企業は事業成長のためにどのような戦略的取り組みを進めているのか？
• Q.10.この市場における競合製品にはどのようなものがあり、材料や製品の代替による市場シェア低下の脅威はどの程度ありますか？
• Q.11.過去5年間にどのようなM&Aが行われ、業界にどのような影響を与えましたか？

目次

第1章 エグゼクティブサマリー

第2章 世界の骨粗鬆症治療薬市場：市場力学

• イントロダクション、背景、分類
• サプライチェーン
• 業界の促進要因と課題

第3章 2018年から2030年までの市場動向と予測分析

• マクロ経済動向（2018～2023年）と予測（2024～2030年）
• 世界の骨粗鬆症治療薬市場の動向（2018～2023年）と予測（2024～2030年）
• 薬剤の種類別の世界の骨粗鬆症治療薬市場
  • 副甲状腺ホルモン療法
  • ビスホスホネート
  • カルシトニン
  • RANKL阻害剤
  • その他
• 用途別の世界の骨粗鬆症治療薬市場
  • 原発性骨粗鬆症
  • 続発性骨粗鬆症

第4章 2018年から2030年までの地域別の市場動向と予測分析

• 地域別の世界の骨粗鬆症治療薬市場
• 北米の骨粗鬆症治療薬市場
• 欧州の骨粗鬆症治療薬市場
• アジア太平洋の骨粗鬆症治療薬市場
• その他地域の骨粗鬆症治療薬市場

第5章 競合分析

• 製品ポートフォリオ分析
• 運用上の統合
• ポーターのファイブフォース分析

第6章 成長機会と戦略的分析

• 成長機会分析
  • 薬剤の種類別の世界の骨粗鬆症治療薬市場の成長機会
  • 用途別の世界の骨粗鬆症治療薬市場の成長機会
  • 地域別の世界の骨粗鬆症治療薬市場の成長機会
• 世界の骨粗鬆症治療薬市場の新たな動向
• 戦略的分析
  • 新製品の開発
  • 世界の骨粗鬆症治療薬市場の能力拡大
  • 世界の骨粗鬆症治療薬市場における合併、買収、合弁事業
  • 認証とライセンシング

第7章 有力企業の企業プロファイル

• Pfizer
• Eli Lily
• F. Hoffmann La Roche
• Merck
• Amgen
• Radius Health
• Teva Pharmaceutical Industries

Osteoporosis Drug Trends and Forecast

The future of the global osteoporosis drug market looks promising with opportunities in the primary osteoporosis and secondary osteoporosis markets. The global osteoporosis drug market is expected to reach an estimated $17.2 billion by 2030 with a CAGR of 3.2% from 2024 to 2030. The major drivers for this market are rising occurrences of osteoporosis and increase in the elderly population across the globe.

.

A more than 150-page report is developed to help in your business decisions.

Osteoporosis Drug by Segment

The study includes a forecast for the global osteoporosis drug by drug type, application, and region.

Osteoporosis Drug Market by Drug Type [Shipment Analysis by Value from 2018 to 2030]:

• Parathyroid Hormone Therapy
• Bisphosphonates
• Calcitonin
• Rankl Inhibitors
• Others

Osteoporosis Drug Market by Application [Shipment Analysis by Value from 2018 to 2030]:

• Primary Osteoporosis
• Secondary Osteoporosis

Osteoporosis Drug Market by Region [Shipment Analysis by Value from 2018 to 2030]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

List of Osteoporosis Drug Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies osteoporosis drug companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the osteoporosis drug companies profiled in this report include-

• Pfizer
• Eli Lily
• F. Hoffmann La Roche
• Merck
• Amgen
• Radius Health
• Teva Pharmaceutical Industries

Osteoporosis Drug Market Insights

Lucintel forecasts that RANKL inhibitor will remain the largest segment over the the forecast period due to its increasing adoption to treat osteoporosis in patients with high risk of fractures.

Within this market, primary osteoporosis will remain the larger segment due to surging aging population and growing awareness towards osteoporosis among consumers.

North America will remain the largest region over the forecast period due to existence of major players, rising prevalence of osteoporosis patients, and easy accessibility of branded medications in the region.

Features of the Global Osteoporosis Drug Market

Market Size Estimates: Osteoporosis drug market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Osteoporosis drug market size by drug type, application, and region in terms of value ($B).

Regional Analysis: Osteoporosis drug market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different drug types, applications, and regions for the osteoporosis drug market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the osteoporosis drug market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the osteoporosis drug market size?

Answer: The global osteoporosis drug market is expected to reach an estimated $17.2 billion by 2030.

Q2. What is the growth forecast for osteoporosis drug market?

Answer: The global osteoporosis drug market is expected to grow with a CAGR of 3.2% from 2024 to 2030.

Q3. What are the major drivers influencing the growth of the osteoporosis drug market?

Answer: The major drivers for this market are rising occurrences of osteoporosis and increase in the elderly population across the globe.

Q4. What are the major segments for osteoporosis drug market?

Answer: The future of the osteoporosis drug market looks promising with opportunities in the primary osteoporosis and secondary osteoporosis markets.

Q5. Who are the key osteoporosis drug market companies?

Answer: Some of the key osteoporosis drug companies are as follows:

• Pfizer
• Eli Lily
• F. Hoffmann La Roche
• Merck
• Amgen
• Radius Health
• Teva Pharmaceutical Industries

Q6. Which osteoporosis drug market segment will be the largest in future?

Answer: Lucintel forecasts that RANKL inhibitor will remain the largest segment over the the forecast period due to its increasing adoption to treat osteoporosis in patients with high risk of fractures.

Q7. In osteoporosis drug market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region over the forecast period due to existence of major players, rising prevalence of osteoporosis patients, and easy accessibility of branded medications in the region.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the osteoporosis drug market by drug type (parathyroid hormone therapy, bisphosphonates, calcitonin, RANKL inhibitors, and others), application (primary osteoporosis and secondary osteoporosis), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Osteoporosis Drug Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

• 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
• 3.2. Global Osteoporosis Drug Market Trends (2018-2023) and Forecast (2024-2030)
• 3.3: Global Osteoporosis Drug Market by Drug Type
  • 3.3.1: Parathyroid Hormone Therapy
  • 3.3.2: Bisphosphonates
  • 3.3.3: Calcitonin
  • 3.3.4: RANKL Inhibitors
  • 3.3.5: Others
• 3.4: Global Osteoporosis Drug Market by Application
  • 3.4.1: Primary Osteoporosis
  • 3.4.2: Secondary Osteoporosis

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

• 4.1: Global Osteoporosis Drug Market by Region
• 4.2: North American Osteoporosis Drug Market
  • 4.2.2: North American Osteoporosis Drug Market by Application: Primary Osteoporosis and Secondary Osteoporosis
• 4.3: European Osteoporosis Drug Market
  • 4.3.1: European Osteoporosis Drug Market by Drug Type: Parathyroid Hormone Therapy, Bisphosphonates, Calcitonin, RANKL Inhibitors, and Others
  • 4.3.2: European Osteoporosis Drug Market by Application: Primary Osteoporosis and Secondary Osteoporosis
• 4.4: APAC Osteoporosis Drug Market
  • 4.4.1: APAC Osteoporosis Drug Market by Drug Type: Parathyroid Hormone Therapy, Bisphosphonates, Calcitonin, RANKL Inhibitors, and Others
  • 4.4.2: APAC Osteoporosis Drug Market by Application: Primary Osteoporosis and Secondary Osteoporosis
• 4.5: ROW Osteoporosis Drug Market
  • 4.5.1: ROW Osteoporosis Drug Market by Drug Type: Parathyroid Hormone Therapy, Bisphosphonates, Calcitonin, RANKL Inhibitors, and Others
  • 4.5.2: ROW Osteoporosis Drug Market by Application: Primary Osteoporosis and Secondary Osteoporosis

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Osteoporosis Drug Market by Drug Type
  • 6.1.2: Growth Opportunities for the Global Osteoporosis Drug Market by Application
  • 6.1.3: Growth Opportunities for the Global Osteoporosis Drug Market by Region
• 6.2: Emerging Trends in the Global Osteoporosis Drug Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Osteoporosis Drug Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Osteoporosis Drug Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Pfizer
• 7.2: Eli Lily
• 7.3: F. Hoffmann La Roche
• 7.4: Merck
• 7.5: Amgen
• 7.6: Radius Health
• 7.7: Teva Pharmaceutical Industries